Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes
Authors: Richard E. Pratley, Lauren G. Kanapka, Michael R. Rickels, Andrew Ahmann, Grazia Aleppo, Roy Beck, Anuj Bhargava, Bruce W. Bode, Anders Carlson, Naomi S. Chaytor, D. Steven Fox, Robin Goland, Irl B. Hirsch, Davida Kruger, Yogish C. Kudva, Carol Levy, Janet B. McGill, Anne Peters, Louis Philipson, Athena Philis-Tsimikas, Rodica Pop-Busui, Viral N. Shah, Michael Thompson, Francesco Vendrame, Alandra Verdejo, Ruth S. Weinstock, Laura Young, Kellee M. Miller
Journal: JAMA (2020)

<h3>Importance</h3> Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes. <h3>Objective</h3> To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes. <h3>Design, Setting, and Participants</h3> Randomized clinical trial conducted at 22 endocrinology practices in the United States among 203 adults at least 60 years of age with type 1 diabetes. <h3>Interventions</h3> Participants were randomly assigned in a 1:1 ratio to use CGM (n = 103) or standard BGM (n = 100). <h3>Main Outcomes and Measures</h3> The primary outcome was CGM-measured percentage of time that sensor glucose values were less than 70 mg/dL during 6 months of follow-up. There were 31 prespecified secondary outcomes, including additional CGM metrics for hypoglycemia, hyperglycemia, and glucose control; hemoglobin A<sub>1c</sub>(HbA<sub>1c</sub>); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate. <h3>Results</h3> Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA<sub>1c</sub>, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during follow-up in the CGM group vs 4.7% (68 minutes per day) and 4.9% (70 minutes per day), respectively, in the standard BGM group (adjusted treatment difference, −1.9% (−27 minutes per day); 95% CI, −2.8% to −1.1% [−40 to −16 minutes per day];<i>P</i> &lt;.001). Of the 31 prespecified secondary end points, there were statistically significant differences for all 9 CGM metrics, 6 of 7 HbA<sub>1c</sub>outcomes, and none of the 15 cognitive and patient-reported outcomes. Mean HbA<sub>1c</sub>decreased in the CGM group compared with the standard BGM group (adjusted group difference, −0.3%; 95% CI, −0.4% to −0.1%;<i>P</i> &lt;.001). The most commonly reported adverse events using CGM and standard BGM, respectively, were severe hypoglycemia (1 and 10), fractures (5 and 1), falls (4 and 3), and emergency department visits (6 and 8). <h3>Conclusions and Relevance</h3> Among adults aged 60 years or older with type 1 diabetes, continuous glucose monitoring compared with standard blood glucose monitoring resulted in a small but statistically significant improvement in hypoglycemia over 6 months. Further research is needed to understand the long-term clinical benefit. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03240432